WASHINGTON — Astellas was so sure that one of its drugs was going to be selected as part of Medicare’s new drug price negotiation program that the company preemptively sued the Biden administration.
But it turns out that its blockbuster drug Xtandi didn’t get picked for the program, after all. So on Wednesday, the company withdrew its lawsuit.
Astellas said in a statement that the company’s choice to withdraw its lawsuit does not change its belief that the drug price negotiation program created in the Inflation Reduction act is “bad policy and unconstitutional.”
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.